Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003563695 | SCV004312663 | uncertain significance | not provided | 2023-08-07 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with NTHL1-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 114 of the NTHL1 protein (p.Gly114Glu). |
Ambry Genetics | RCV004654265 | SCV005140452 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-05-01 | criteria provided, single submitter | clinical testing | The p.G114E variant (also known as c.341G>A), located in coding exon 2 of the NTHL1 gene, results from a G to A substitution at nucleotide position 341. The glycine at codon 114 is replaced by glutamic acid, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |